论文部分内容阅读
目的探讨99mTc-MDP(99m锝-亚甲基二膦酸盐)全身骨显像对骨转移瘤的诊断价值。方法常规采用99 mTC-MDP为显像剂,对临床诊断为肺癌、乳腺癌、前列腺癌的230例患者进行核素全身骨显像。结果 230例癌症患者核素骨显像示骨转移者136例,阳性率58.3%,其中肺癌100例,骨转移68例,阳性率68%;乳腺癌100例,骨转移49例,阳性率49%;前列腺癌30例,骨转移19例,阳性率63%。结论肺、乳腺、前列腺癌患者核素骨显像对病程分期、治疗方案选择及预后评估均有重要的临床参考价值。
Objective To investigate the diagnostic value of 99mTc-MDP (99mTc-methylene diphosphonate) whole body bone imaging in bone metastases. Methods 99 mTC-MDP was routinely used as a imaging agent for radionuclide bone imaging in 230 patients with clinically diagnosed lung cancer, breast cancer, and prostate cancer. Results Of the 230 cancer patients, there were 136 cases of radionuclide bone metastasis with a positive rate of 58.3%, of which 100 were lung cancer and 68 were bone metastases. The positive rate was 68%. Breast cancer was 100 and bone metastasis was 49. The positive rate was 49 %; 30 cases of prostate cancer, bone metastasis in 19 cases, the positive rate of 63%. Conclusions Radionuclide bone imaging in patients with lung, breast and prostate cancer has important clinical reference value for the staging of disease, the choice of treatment options and the prognosis.